Trial
NCT05361109
Baricitinib for Cutaneous Dermatomyositis
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Washington
Collaborators
—
Condition
Dermatomyositis
Intervention
Baricitinib
Why stopped
Difficulty recruiting subjects
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-09-01